8月12日 - ** 药物开发商 Cognition Therapeutics 的股票在延时交易中上涨 16.4% 至 1.28 美元
** Cognition Therapeutics 正在开发一种名为 zervimesine 的实验性药片，用于治疗阿尔茨海默病患者。
* (link) * Cognition Therapeutics 正在开发一种名为 zervimesine 的实验性药物，用于治疗阿尔茨海默病患者。
** Cognition Therapeutics 公司总裁兼首席执行官 Lisa Ricciardi 说："会议最重要的成果之一是，FDA 认为两项为期六个月的三期研究可以支持 zervimesine 的新药申请。
** CGTX 的股价今年以来上涨了 55.6
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.